Click here to sign in with or
Forget Password?
Learn more
share this!
12
7
Share
Email
November 17, 2022 report
by Bob Yirka , Medical Xpress
A team of researchers at AstraZeneca, working with colleagues from the University of Mexico and the University of Oxford, has found that a protein tied to the MAP3K15 gene variant may represent a potential target for managing both type I and type II diabetes. The paper is published in the journal Science Advances.
Both types of diabetes have been shown to give rise to multiple health problems, such as heart disease, kidney failure and blindness. And while there is no cure for the disease, many therapies have been developed to prevent some of the damage it can cause.
In this new effort, the researchers looked for commonalities in the genomes of people who have diabetes, as a means for developing new therapies. To that end, they ran search algorithms on data held in the U.K. Biobank.
In all, they found relevant data on 412,000 individuals who had various levels of the disease with a pattern of sorts: higher levels of proteins associated with the MAP3K15 variant. They found that recessive carriers of the variant were 30% less likely to develop diabetes and/or some of the complications that result from the increase in glycosylated hemoglobin levels that are typically seen with the disease.
The researchers suggest that a therapy targeting such proteins could prove useful both in preventing the onset of diabetes and in reducing the harm it causes in those who are afflicted.
The researchers ran the same study using data from the Admixed Americans database used in the Mexico City Prospective Study and also from the FinnGen database. They found similar results, though they also found a link between individuals with the SLC16A11 gene.
The finding, they noted, suggested that treatments developed to target MAP3K15 could be less effective in people with the SLC16A11 variant. They also found that individuals with the MAP3K15 variant who also had the Arg1122 variant were more prevalent in people living in Finland, the country with the highest rate of type 1 diabetes.
The researchers then looked to see if there might be a link between the MAP3K15 variant and a propensity for obesity or elevated cholesterol levels and found none.
© 2022 Science X Network
Explore further
Facebook
Twitter
Email
Feedback to editors
21 hours ago
0
Nov 16, 2022
0
Nov 14, 2022
0
Nov 14, 2022
0
Nov 10, 2022
0
4 hours ago
4 hours ago
4 hours ago
14 hours ago
14 hours ago
15 hours ago
15 hours ago
16 hours ago
16 hours ago
16 hours ago
Aug 17, 2022
Oct 26, 2022
Nov 16, 2022
Jun 09, 2022
Jun 18, 2021
Nov 19, 2019
4 hours ago
18 hours ago
20 hours ago
15 hours ago
18 hours ago
Nov 16, 2022
Use this form if you have come across a typo, inaccuracy or would like to send an edit request for the content on this page. For general inquiries, please use our contact form. For general feedback, use the public comments section below (please adhere to guidelines).
Please select the most appropriate category to facilitate processing of your request
Thank you for taking time to provide your feedback to the editors.
Your feedback is important to us. However, we do not guarantee individual replies due to the high volume of messages.
Your email address is used only to let the recipient know who sent the email. Neither your address nor the recipient’s address will be used for any other purpose. The information you enter will appear in your e-mail message and is not retained by Medical Xpress in any form.
Get weekly and/or daily updates delivered to your inbox. You can unsubscribe at any time and we’ll never share your details to third parties.
More information Privacy policy
Daily science news on research developments and the latest scientific innovations
The latest engineering, electronics and technology advances
The most comprehensive sci-tech news coverage on the web
This site uses cookies to assist with navigation, analyse your use of our services, collect data for ads personalisation and provide content from third parties. By using our site, you acknowledge that you have read and understand our Privacy Policy and Terms of Use.